Brief: Hansa Biopharma Q4 EBIT SEK -177 Million
06/01/2024 13:00
Jan 06 (Reuters) - Hansa Biopharma Q4 revenue SEK 50 million. * Q4 cash & investments SEK 732 million
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS